As of June 8, 2025, Wuhan Hvsen Biotechnology Co Ltd (300871.SZ) reports a ROA (Return on Assets) of -0.67%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Wuhan Hvsen Biotechnology Co Ltd's ROA (Return on Assets)
Over recent years, Wuhan Hvsen Biotechnology Co Ltd's ROA (Return on Assets) has shown significant volatility. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -0.67% |
| 2023-12-31 | 0.56% |
| 2022-12-31 | 1.76% |
| 2021-12-31 | 4.85% |
| 2020-12-31 | 8.57% |
This gradual decrease highlights how Wuhan Hvsen Biotechnology Co Ltd manages its efficiency in using assets to generate earnings over time.
Comparing Wuhan Hvsen Biotechnology Co Ltd's ROA (Return on Assets) to Peers
To better understand Wuhan Hvsen Biotechnology Co Ltd's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Wuhan Hvsen Biotechnology Co Ltd (300871.SZ) | -0.67% |
| Hunan Jiudian Pharmaceutical Co Ltd (300705.SZ) | 15.19% |
| Tibet Weixinkang Medicine Co Ltd (603676.SS) | 13.28% |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181.SZ) | 12.72% |
| Aurisco Pharmaceutical Co Ltd (605116.SS) | 11.24% |
| Jiangsu Jibeier Pharmaceutical Co Ltd (688566.SS) | 8.68% |
Compared to its competitors, Wuhan Hvsen Biotechnology Co Ltd's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.